NCT04590547 - GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

May 7, 2021

Primary Completion Date

August 14, 2022

Study Completion Date

July 24, 2023

Conditions

PneumonitisSARS-CoV Infection

Interventions

DRUG

GLS-1027

GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.

DRUG

Placebo

Placebo looks like GLS-1027

Trial Locations (17)

Baton Rouge General Medical Center, Baton Rouge

MHAT Kozlodui, Kozloduy

SHATPPD d-r Dimitar Gramatikov, Department of Pneumology, Rousse

UMHAT MEDICA RUSE LTD, Internal Diseases Department/Covid, Rousse

Military MHAT Sliven, Sliven

UHAT Aleksandrovska, Sofia

PHI Clinical Hospital - Shtip, Department for Infectious Diseases and Febrile Conditions, Skopje

"PHI General City Hospital 8mi Septemvri - COVID-19 Intensive Care Department", Skopje

PHI University Clinic for Pulmonology and Allergology, Skopje

PHI University Clinic of Infectious Diseases and Febrile Conditions, Skopje

"PHI General Hospital Struga bb, Quay 8-mi Noemvri", Struga

Korea University Ansan Hospital, Ansan-si

Gachon University Gil Medical Center, Incheon

Inha University Hospital, Incheon

Korea University Anam Hospital, Seoul

Korea University Guro Hospital, Seoul

University of Puerto Rico, San Juan